Value proposition

Enabling Cancer Treatment Breakthroughs

Carcinotech provides comprehensive solid tumour research services to therapeutic developers and healthcare professionals. At the heart of its offerings is the proprietary Carcino3DTM bioprinting platform, which creates assay-ready, 3D tumours from patient biopsies.

Unlike conventional cancer models, Carcinotech’s bioprinted constructs incorporate multiple cell types—including immune cell populations—within a robust tissue matrix, offering a more biologically relevant and controlled model for early drug discovery, preclinical and co-clinical studies, and personalised treatment testing.

Cancer research, 3D bioprinting , Drug discovery , Cancer microenvironment, Personalised medicine testing, drug testing, oncology, assay services, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, immuno-oncology, early phase drug development, and early drug discovery